Amplyx Pharmaceuticals Inc.grew closer to bringing a new class of antifungal therapy to patients on 16 September after a pair of data review boards monitoring its Phase II trial of fosmanogepix in candidemia infections approved enrolling the second half of the study.
If approved, fosmanogepix (APX001) would be a first-in-class gepix antifungal agent and offer an intravenous-to-oral course of therapy to patients...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)